Literature DB >> 12069813

Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction.

Yan Xu1.   

Abstract

In recent years, certain lysophospholipids (lyso-PLs) have been recognized as important cell signaling molecules. Among them, two phosphorylcholine-containing lyso-PLs, sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC), have been shown to be involved in many cellular processes and are produced under physiological and pathological conditions. Although signaling properties of SPC and LPC have been studied in a variety of cellular systems, specific cell membrane receptors for SPC and LPC have not been identified previously. Recently, ovarian cancer G protein-coupled receptor 1 (OGR1, also known as GPR68), G protein-coupled receptor 4 (GPR4), and G2A have been identified as receptors for SPC and LPC. The signaling and ligand-binding properties of these receptors are reviewed here. These discoveries provide an intriguing opportunity and a novel approach in studying the pathophysiological roles of SPC and LPC and their receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069813     DOI: 10.1016/s1388-1981(02)00140-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  52 in total

1.  Modulation of ecto-5'-nucleotidase by phospholipids in human umbilical vein endothelial cells (HUVEC).

Authors:  Annette Pexa; Andreas Deussen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

2.  Sphingosine-1-phosphate and sphingosylphosphorylcholine: two of a kind?

Authors:  Astrid E Alewijnse; Martin C Michel
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Differential effects of lysophosphatidylcholine and ACh on muscarinic K(+),non-selective cation and Ca(2+) currents in guinea-pig atrial cells.

Authors:  Libing Li; Isao Matsuoka; Kazuho Sakamoto; Junko Kimura
Journal:  Fukushima J Med Sci       Date:  2016-02-25

Review 4.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

6.  RNAi targeting GPR4 influences HMEC-1 gene expression by microarray analysis.

Authors:  Juan Ren; Yuelang Zhang; Hui Cai; Hongbing Ma; Dongli Zhao; Xiaozhi Zhang; Zongfang Li; Shufeng Wang; Jiangsheng Wang; Rui Liu; Yi Li; Jiansheng Qian; Hongxia Wei; Liying Niu; Yan Liu; Lisha Xiao; Muyang Ding; Shiwen Jiang
Journal:  Int J Clin Exp Med       Date:  2014-03-15

7.  Regulation of eosinophil adhesion by lysophosphatidylcholine via a non-store-operated Ca2+ channel.

Authors:  Xiangdong Zhu; Jonathan Learoyd; Sanober Butt; Lilly Zhu; Peter V Usatyuk; Viswanathan Natarajan; Nilda M Munoz; Alan R Leff
Journal:  Am J Respir Cell Mol Biol       Date:  2007-01-11       Impact factor: 6.914

8.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling.

Authors:  Stefano Costanzi; Liaman Mamedova; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

9.  Characterization of human lysophospholipid acyltransferase 3.

Authors:  Shilpa Jain; Xiaoling Zhang; Preeti J Khandelwal; Aleister J Saunders; Brian S Cummings; Peter Oelkers
Journal:  J Lipid Res       Date:  2009-04-07       Impact factor: 5.922

10.  Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.

Authors:  Lin Ma; Hitoshi Uchida; Jun Nagai; Makoto Inoue; Jerold Chun; Junken Aoki; Hiroshi Ueda
Journal:  Mol Pain       Date:  2009-11-13       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.